Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest-Reference-Cited by-同舟云学术

Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest

Published:2023-06-21 Issue:1 Volume:34 Page:
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Egeberg Alexander¹,Jullien Denis²,Gaarn Du Jardin Kristian³,Thaçi Diamant⁴

Affiliation:

1. Department of Dermatology, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark

2. Hospices Civils de Lyon, Hôpital E. Herriot, Service de Dermatologie, Université Lyon-1; INSERM Unité, Lyon, France

3. Almirall R&D, Barcelona, Spain

4. Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany

Funder

Almirall R&D, Barcelona, Spain

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2023.2220447

Reference17 articles.

1. Psoriasis

2. Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*

3. Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients

4. Tildrakizumab: short‐term efficacy and safety in real clinical practice

5. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting;Burlando M;Drugs Context,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Activation of the interleukin-23/Th17 axis in major depression: a systematic review and meta-analysis;European Archives of Psychiatry and Clinical Neuroscience;2024-07-16

2. Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018–2023;Frontiers in Pharmacology;2024-07-10

3. Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities;Dermatology and Therapy;2024-04

4. Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden;Expert Opinion on Biological Therapy;2024-03-03